Celldex Therapeutics

Update in progress

CLDX (NasdaqCM)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Celldex Therapeutics is a biopharmaceutical company developing therapeutic antibodies for severe inflammatory, allergic, autoimmune, and related diseases. Its programs focus on mast cell–driven conditions with limited treatments. Lead candidates include Barzolvolimab (CDX-0159), a monoclonal antibody that binds the KIT receptor to inhibit its activity, for chronic urticaria, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis. CDX-622 is a bispecific candidate targeting two inflammatory pathways, neutralizing thymic stromal lymphopoietin and depleting mast cells via stem cell factor starvation. The company is headquartered in Hampton, New Jersey.

Company score

Sentiment: 0.24; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.20; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.03; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.06; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.15; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive